Melanoma that proliferates from pigment-producing melanocytes is the deadliest form of skin cancer, which can be caused by extensive ultraviolet light exposure, especially in individuals with low levels of melanin. A
2025
NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma
NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
Considering the Changing Treatment Landscape for Patients With Melanoma
Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses the evolving treatment landscape for advanced melanoma.
Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Second-line adjuvant treatment with dabrafenib and trametinib appeared effective in a small study of patients with BRAF V600-mutated, resected, stage III/IV melanoma, researchers found. In fact, more than 80% of patients were free from relapse and metastasis at 1 year. These results were published in The Oncologist.